SubsidieMeestersSmart RNA delivery for therapy and diagnostic
This project aims to develop peptide-based carriers for effective delivery of double-stranded RNA in cells, identifying candidates for potential commercial partnerships.
Projectdetails
Introduction
The progression of RNA-based cellular applications in molecular therapy has been greatly hindered due to the difficulty of delivering RNA across biological barriers.
Background
Interest has therefore grown in the development of carrier systems which can facilitate RNA delivery in a controlled manner.
Project Objectives
Herein, we use peptide-based binders to stabilize and deliver double-stranded RNA. The main goals of this project are:
- The identification of lead candidates with robust cell delivery in relevant cell lines.
- To be fit for partnering with a company and/or securing follow-up resources.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-4-2023 |
| Einddatum | 30-9-2024 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- STICHTING VUpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Conjugation of NAD-capped RNAs to proteins by ADP-ribosyltransferases to generate RNA therapeuticsThis project aims to develop RNAylated proteins as innovative RNA therapeutics by establishing design principles and delivery strategies to regulate cellular processes, including targeting the p53 protein. | ERC Starting... | € 1.499.162 | 2024 | Details |
Kits for advanced polymer-lipid nanocarriers for targeted delivery of RNAs to cardiac and skeletal muscle cellsPOLIRNA aims to develop a versatile platform for safe and efficient RNA delivery to target multiple cell types, enhancing preclinical research in cardiac and muscle-related diseases. | ERC Proof of... | € 150.000 | 2023 | Details |
Targeting long non-coding RNAs for novel treatment strategies in vascular diseasesThis project aims to identify and target specific long non-coding RNAs involved in vascular diseases using innovative RNA interference strategies to improve treatment outcomes. | ERC Consolid... | € 1.999.495 | 2023 | Details |
nanoVAST: a novel, non- viral LNP for precision payload delivery of genome editors and other cargoThe project aims to develop the nanoVAST system for targeted RNA delivery to CD19+ B cells, enhancing specificity and efficiency while avoiding the drawbacks of current delivery methods. | ERC Proof of... | € 150.000 | 2022 | Details |
Unravelling extracellular vesicle heterogeneity to inspire improved therapeutic RNA delivery systemsUNRAVEL aims to characterize extracellular vesicle subpopulations for enhanced RNA delivery, leading to the development of biomimetic synthetic RNA delivery systems to improve therapeutic applications. | ERC Consolid... | € 2.000.000 | 2025 | Details |
Conjugation of NAD-capped RNAs to proteins by ADP-ribosyltransferases to generate RNA therapeutics
This project aims to develop RNAylated proteins as innovative RNA therapeutics by establishing design principles and delivery strategies to regulate cellular processes, including targeting the p53 protein.
Kits for advanced polymer-lipid nanocarriers for targeted delivery of RNAs to cardiac and skeletal muscle cells
POLIRNA aims to develop a versatile platform for safe and efficient RNA delivery to target multiple cell types, enhancing preclinical research in cardiac and muscle-related diseases.
Targeting long non-coding RNAs for novel treatment strategies in vascular diseases
This project aims to identify and target specific long non-coding RNAs involved in vascular diseases using innovative RNA interference strategies to improve treatment outcomes.
nanoVAST: a novel, non- viral LNP for precision payload delivery of genome editors and other cargo
The project aims to develop the nanoVAST system for targeted RNA delivery to CD19+ B cells, enhancing specificity and efficiency while avoiding the drawbacks of current delivery methods.
Unravelling extracellular vesicle heterogeneity to inspire improved therapeutic RNA delivery systems
UNRAVEL aims to characterize extracellular vesicle subpopulations for enhanced RNA delivery, leading to the development of biomimetic synthetic RNA delivery systems to improve therapeutic applications.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
TraffikGene-Tx: Targeted Peptide Carriers for RNA DeliveryTraffikGene-Tx aims to develop safe, scalable peptide carriers for targeted RNA delivery, addressing genetic diseases and enhancing NAT therapies to improve patient outcomes and reduce healthcare costs. | EIC Transition | € 2.498.963 | 2023 | Details |
A revolutionary cell programming platform based on the targeted nano-delivery of a transposon gene editing systemThe NANO-ENGINE project aims to develop an affordable, scalable, and safe DNA-based in vivo cell programming technology using Targeted Nanoparticles to enhance accessibility of cell therapies for various diseases. | EIC Pathfinder | € 2.988.377 | 2023 | Details |
New Prime Editing and non-viral delivery strategies for Gene TherapyThis project aims to develop non-viral delivery systems and novel prime editors to enhance gene editing efficiency and safety for treating Sickle Cell Disease and other genetic disorders. | EIC Pathfinder | € 4.406.097 | 2022 | Details |
NOn-VIral gene modified STEM cell therapyThis project aims to develop a high-throughput protocol for producing gene-corrected CAR T cells and blood stem cells using optimized photoporation and CRISPR technology for enhanced clinical application. | EIC Pathfinder | € 3.644.418 | 2022 | Details |
ARISE - Advanced RNA Inhalation Solutions anchored in Evolved dry powder technology.RNhale's project aims to revolutionize RNA therapeutics for pulmonary diseases by developing inhalable dry powder formulations of RNA encapsulated in lipid nanoparticles. | EIC Transition | € 2.421.498 | 2025 | Details |
TraffikGene-Tx: Targeted Peptide Carriers for RNA Delivery
TraffikGene-Tx aims to develop safe, scalable peptide carriers for targeted RNA delivery, addressing genetic diseases and enhancing NAT therapies to improve patient outcomes and reduce healthcare costs.
A revolutionary cell programming platform based on the targeted nano-delivery of a transposon gene editing system
The NANO-ENGINE project aims to develop an affordable, scalable, and safe DNA-based in vivo cell programming technology using Targeted Nanoparticles to enhance accessibility of cell therapies for various diseases.
New Prime Editing and non-viral delivery strategies for Gene Therapy
This project aims to develop non-viral delivery systems and novel prime editors to enhance gene editing efficiency and safety for treating Sickle Cell Disease and other genetic disorders.
NOn-VIral gene modified STEM cell therapy
This project aims to develop a high-throughput protocol for producing gene-corrected CAR T cells and blood stem cells using optimized photoporation and CRISPR technology for enhanced clinical application.
ARISE - Advanced RNA Inhalation Solutions anchored in Evolved dry powder technology.
RNhale's project aims to revolutionize RNA therapeutics for pulmonary diseases by developing inhalable dry powder formulations of RNA encapsulated in lipid nanoparticles.